Drugs / botulism immune globulin
botulism immune globulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT00004401 | Jan → Jun 1998 | infant botulism | California Department of Health Services | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | botulism immune globulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004401 ↗ |
| Known as | BIG | “Patients should begin therapy within 72 hours of hospital admission, but may receive human botulism immunoglobulin (BIG) in certain circumstances after 72 hours.” NCT00004401 ↗ |
| Known as | human botulism immunoglobulin | “Patients should begin therapy within 72 hours of hospital admission, but may receive human botulism immunoglobulin (BIG) in certain circumstances after 72 hours.” NCT00004401 ↗ |
| Modality | Protein / enzyme biologic | “human botulism immunoglobulin (BIG)” NCT00004401 ↗ |
| Route | Intravenous | “Patients receive (BIG) IV.” NCT00004401 ↗ |